Main: to demonstrate the bioequivalence of the new buprenorphine transdermal patch T2rev formulation containing 13 mg buprenorphine (Test) as compared to Transtec (R) PRO 70 µg/h patch transdermal patch containing 40 mg buprenorphine as reference (Reference) after single patch application. Pharmacokinetic target parameters are AUC, AUCo-t, and Cmax.